<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">121496</article-id><article-id pub-id-type="doi">10.23868/gc121496</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effective Transduction of Human Adipose Stromal Cells by a Recombinant Adeno-Associated Virus</article-title><trans-title-group xml:lang="ru"><trans-title>Эффективная трансдукция стромальных клеток жировой ткани человека с помощью рекомбинантного аденоассоциированного вируса</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Shevchenko</surname><given-names>E K</given-names></name><name xml:lang="ru"><surname>Шевченко</surname><given-names>Е К</given-names></name></name-alternatives><bio xml:lang="en"><p>The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical Care</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Makarevich</surname><given-names>P I</given-names></name><name xml:lang="ru"><surname>Макаревич</surname><given-names>П И</given-names></name></name-alternatives><bio xml:lang="en"><p>The Faculty of Fundamental Medicine, Lomonosov Moscow State University</p></bio><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Tsokolaeva</surname><given-names>Z I</given-names></name><name xml:lang="ru"><surname>Цоколаева</surname><given-names>З И</given-names></name></name-alternatives><bio xml:lang="en"><p>The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical Care</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ratner</surname><given-names>E I</given-names></name><name xml:lang="ru"><surname>Ратнер</surname><given-names>Е И</given-names></name></name-alternatives><bio xml:lang="en"><p>The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical Care</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Parfionova</surname><given-names>E V</given-names></name><name xml:lang="ru"><surname>Парфенова</surname><given-names>Е В</given-names></name></name-alternatives><bio xml:lang="en"><p>The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical CareThe Faculty of Fundamental Medicine, Lomonosov Moscow State University</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical Care</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">The Faculty of Fundamental Medicine, Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">The Institute of Experimental Cardiology of the FSI Russian Cardiologic Research-and-Production Complex of the Federal Agency of High-Tech Medical CareThe Faculty of Fundamental Medicine, Lomonosov Moscow State University</institution></aff><aff><institution xml:lang="ru"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2010-03-15" publication-format="electronic"><day>15</day><month>03</month><year>2010</year></pub-date><volume>5</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2010)</issue-title><issue-title xml:lang="ru">№1 (2010)</issue-title><fpage>60</fpage><lpage>64</lpage><history><date date-type="received" iso-8601-date="2023-01-11"><day>11</day><month>01</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2010, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2010, Эко-Вектор</copyright-statement><copyright-year>2010</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/121496">https://genescells.ru/2313-1829/article/view/121496</self-uri><abstract xml:lang="en"><p>Despite the initial indications of positive therapeutic effects in cell therapy there are still limitations in numbers of autologous cell populations available without significant ex vivo expansion. Autologous adipose stromal cells CASCJ transplantation due to sufficient cell numbers, their multipotency and the ability to secret angiogenic growth factors may become an alternative tool to treat cardiovascular diseases. In this study we Investigated the ability to efficiently transfer gene into such cells using plasmid and recombinant adeno-associated virus (rAAVJ. Human ASC were isolated from adipose tissue obtained from different donors during surgical operations. Low passaged cells were transduced using gene delivery system CStratagene] based on recombinant adeno-associated virus (rAAVJ serotype 2 encoding human vascular endothelial growth factor (VEGF) or green fluorescent protein (GFP). Transduction efficiencies and transgene expression level in ASCs were analyzed by quantitative flow cytometry and ELISA. ASC population was analysed for heparan sulfate proteoglycan expression, the main cellular AAV binding receptor. It was found that 55-65% of human ASC population express this receptor. The efficiency of ASC transduction using AAV delivery system was found to be 60+7%. GFP expression was visible during a month. Relative to control, cells transduced by VEGF rAAV vector increased VEGF secretion level by at least 20-30 fold as compared to unmanipulated ASC. Recombinant adeno-associated virus provides efficient tools for ex vivo modification of human ASCs.</p></abstract><trans-abstract xml:lang="ru"><p>Наиболее перспективное направление в клеточной трансплантологии - использование генетически модифицированных клеток - своеобразный альянс клеточной и генной терапии. Стро-мальные клетки жировой ткани ССКЖП благодаря возможности выделения их в большом количестве у пациентов при минимальном хирургическом вмешательстве, а также высокому уровню экспрессии ими различных митогенных, антиапоптотических и ангиогенных факторов могут стать важнейшим инструментом клеточной терапии сердечно-сосудистых заболеваний. В данной работе изучена возможность генетического модифицирования СКЖТ человека с помощью плазмидных конструкций и рекомбинантного аденоассоциированного вируса CpAABJ. СКЖТ человека выделяли из жировой ткани доноров, взятой при хирургической операции. Клетки на ранних пассажах трансфицировали плазмидой pcDNA3GFP, используя различные протоколы, а также трансдуцировали рААВ, несущим ген зеленого флуоресцентного белка [GFPJ, либо VEGF. Эффективность трансдукции клеток определяли микроскопическим анализом и методом проточной цитофлуориметрии. Уровень экспрессии трансгена анализировали с помощью иммунофер-ментного анализа и иммуноблоттинга. С помощью проточной цитофлуориметрии определили наличие в популяции СКЖТ клеток, которые несут на своей поверхности гепарансульфат протеогликан, рецептор, через который происходит связывание вируса с клеткой. Было показано, что 55-85% популяции СКЖТ экспрессируют данный белок. Эффективность трансдукции СКЖТ рекомбинантным вирусом, выраженная в процентном содержании флуоресцирующих, GFP-позитивных, клеток, составила 60+7%. Флуоресценцию GFP наблюдали, в течение месяца. Клетки, трансдуцированные вирусом с VEGF, секретировали в 20-30 раз больше белка по сравнению с немодифицированными клетками. Впервые показана возможность использования рекомбинантного адено-ассоциированного вируса человека для эффективной доставки терапевтического гена в стромальные клетки жировой ткани человека.</p></trans-abstract><kwd-group xml:lang="en"><kwd>stromal cells</kwd><kwd>transduction</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>стромальные клетки</kwd><kwd>трансдукция</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Zuk Р.А., Zhu М., Ashjian P. et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell. 2002; 13(12): p. 4279-95.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Planat-Benard V., Silvestre J.S., Cousin B. et al. Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004; 109(5): 65B-B3.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Seo M.J., Suh S.Y., Bae Y.C. et al. Differentiation of human adipose stromal cells into hepatic lineage in vitro and in vivo. Biochem Biophys Res Commun. 2005; 328(1): 258-64.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Strem B.M., Zhu M., Alfonso Z. et al. Expression of cardiomyocytic markers on adipose tissue-derived cells in a murine model of acute myocardial injury. Cytotherapy 2005; 7(3): 282-91.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Rehman J., Traktuev D., Li J. et al., Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004; 109(10): 1292-8.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>В. Трактуев Д.О., T.B.A., Марч К.П., Парфенова Е.В., Стромальные клетки жировой ткани - мультипотентные клетки с терапевтическим потенциалом для стимуляции ангиогенеза при ишемии тканей. Кардиология 2006. 46: 53-63.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Nakagami Н., Maeda К., Morishita R. et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vase Biol. 2005; 25(12): 2542-7.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Traktuev D.O., Prater D.N., Merfeld-Clauss S. et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. Circ Res. 2009; 104(12): 1410-20.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Kwon I., Schaffer D.V. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer. Pharm Res. 2008; 25(3): 489-99.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Buning H., Perabo L, Coutelle 0. et al. Recent developments in adeno-associated virus vector technology. J Gene Med. 2008; 10(7): 717-33.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Smith R.H. Adeno-associated virus integration: virus versus vector. Gene Ther. 2008; 15(11): 817-22.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>McCarty D.M., Young S.M., Samulski R.J. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet. 2004; 38: 819-45.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Peden C.S., Burger C, Muzyczka N. et al. Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol. 2004; 78(12): 6344-59.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Moskalenko M., Chen L, van Roey M. et al. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol. 2000; 74(4): 1761-6.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Summerford C, Samulski R.J. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol. 1998; 72(2): 1438-45.</mixed-citation></ref></ref-list></back></article>
